% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:22775,
      author       = {Galldiks, N. and Filss, C.P. and Goldbrunner, R. and
                      Langen, K.-J.},
      title        = {{D}iscrepant {MR} and [18{F}]{F}luoroethyl-{L}-{T}yrosine
                      {PET} imaging findings in a patient with bevacizumab
                      failure},
      journal      = {Case reports in oncology},
      volume       = {5},
      issn         = {1662-6575},
      address      = {Basel},
      publisher    = {Karger},
      reportid     = {PreJuSER-22775},
      pages        = {490 - 494},
      year         = {2012},
      note         = {Record converted from VDB: 12.11.2012},
      abstract     = {Photodynamic therapy (PDT) has become a well-established
                      treatment for vascular forms of age-related macular
                      degeneration (AMD). The implementation of evidence-based
                      medicine principles into the treatment regimen of AMD seems
                      to be immensly important, since AMD continues to be the most
                      frequent cause of blindness among patients older than 65
                      years in industrialized countries. Numerous randomized
                      prospective studies demonstrated high levels of evidence for
                      the efficacy of various treatment approaches such as laser
                      photocoagulation, PDT, subretinal surgery or novel
                      anti-angiogenic drugs [Arch Ophthalmol 2006;124:597-599].
                      The high evidence shown by these studies supported the
                      rationale to use PDT also in additional, less frequent,
                      vasoproliferative diseases. Although these 'case series' and
                      'individual case control studies' have a low level of
                      evidence, they give us important information for treatment
                      decisions in these rare conditions. The goal of this survey
                      is to review the current literature regarding PDT in
                      vasoproliferative and exudative ocular diseases outside AMD.
                      Many studies modified the treatment parameters of PDT to
                      address the specific pathology of the underlying disease.
                      Table 1 summarizes the diseases and treatment parameters
                      that are described in this part 2, the entire table of this
                      review is included in part 1 (www.karger.com/doi/10.1159/
                      000101922).},
      keywords     = {Exudates and Transudates: metabolism / Eye Diseases: drug
                      therapy / Eye Diseases: metabolism / Eye Neoplasms: drug
                      therapy / Humans / Neovascularization, Pathologic: drug
                      therapy / Photochemotherapy: trends},
      cin          = {INM-3 / INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {Funktion und Dysfunktion des Nervensystems},
      pid          = {G:(DE-Juel1)FUEK409},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:17728549},
      doi          = {10.1159/000342480},
      url          = {https://juser.fz-juelich.de/record/22775},
}